viewOpen Orphan PLC

Open Orphan joins global effort to tackle coronavirus pandemic


  • Merger with hVIVO completed in January 2020 to create European full pharma services company
  • Testing Covid-19 treatment while new contracts are underway
Open Orphan

Quick facts: Open Orphan PLC

Price: 13.7599 GBX

Market: AIM
Market Cap: £91.59 m


What it does

Open Orphan Plc was established in 2017 to build a platform that helps pharma companies commercialise their products in Europe, with a specific focus on drugs that treat rare diseases.

Since then, it has built a database of all the firms with orphan drugs that have either been approved or are currently going through the clinic.

Open Orphan has also put together a 4,000-strong directory of physicians and key opinion leaders with expertise in marketing and selling orphan drugs.

Normally, drug developers would have to pay a handsome fee to a third-party to help find those experts, but Open Orphan intends to undercut the market with a cheaper annual subscription which gives the drug companies access to the platform.

At the moment, Open Orphan is more of a ‘virtual rep’ service, which can be used to support the launch of new products or to promote mature brands.

But executive chairman Cathal Friel and his team want to grow the company into a full-service consultancy for orphan and rare disease drugs.

In January, Open Orphan merged with challenge trial specialist hVIVO PLC (LON:HVO), whose shareholders ended up owning around 44.7% of the combined entity.


How it is doing

In March, hVIVO began the world’s first human coronavirus challenge study.

Also known as a controlled human infection model, at its simplest, it is a method of testing potential vaccines against certain illnesses in a locked-down medical facility.

In April it started testing an anti-viral drug for treating coronavirus on behalf of its client Nearmedic International.

Nearmedic is a specialist pharmaceutical, biotechnological and medical business headquartered in Moscow; it is running tests using hVIVO's virology expertise and laboratory capability on an anti-viral drug that could potentially be used to combat SARS-CoV2 (COVID-19) infections.

Also in April, Open Orphan signed a new contract with a US biotechnology company for the provision of a respiratory syncytial virus human challenge study, expected to rack up £3.5mln in revenue. This new contract follows the signing in March of another respiratory syncytial virus (RSV) human challenge contract, now underway, for an initial £3.2mln.

In May, this was followed by a manufacturing tie-up with Quotient Limited.

What the boss says: Cathal Friel, executive chairman

“The signing of this new £3.5mln contract with a US biotechnology company is further evidence of this exciting time as we successfully convert Open Orphan's pipeline of prospects into formal customer contracts."

"Open Orphan will be utilising its complementary in-house CRO services of hVIVO and Venn to deliver this contract. This contract demonstrates the Open Orphan and hVivo group's focus on building long term contracts with recurring revenues to deliver future profitability while ensuring rationalising the business and reduce costs.”


Read the latest research update: Open Orphan focused on a buoyant outlook

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...



Analyst Ryan Long asks if we could be facing a sustained uptrend in the...

Proactive analyst Ryan Long says silver has been turning heads in recent months and there are signs of a sustained near-term uptrend that could extend for some time. He says the gold-silver ratio has now risen from a low of 34.7:1 in April 2011, its lowest level since 1979, to its highest level...

4 hours, 47 minutes ago

3 min read